Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Book value per share
Zymeworks Inc.'s book value per share at the end of fiscal 2025 was 3.6×, down 20.3% from 4.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 1.1×. Over the past ten years it has ranged from 0.7× (fiscal 2015) to 8.1× (fiscal 2020); the current reading is higher than 18% of that period. Zymeworks Inc. ranks 340th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.6× | (20.28%) |
| FY2024 | 4.5× | (33.83%) |
| FY2023 | 6.7× | (10.73%) |
| FY2022 | 7.6× | 56.49% |
| FY2021 | 4.8× | (40.61%) |
| FY2020 | 8.1× | 25.92% |
| FY2019 | 6.5× | 4.14% |
| FY2018 | 6.2× | 13.24% |
| FY2017 | 5.5× | 2.84% |
| FY2016 | 5.3× | 685.51% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 1.1× | (49.75%) |
| Mar 2026 | 2.2× | (38.47%) |
| Dec 2025 | 3.6× | (15.71%) |
| Sep 2025 | 4.2× | (4.86%) |
| 39 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| COAG Hemab Therapeutics Holdings, Inc. compare | 15.1× |
| SEPN Septerna, Inc. compare | 8.6× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ZYME Zymeworks Inc. | 1.1× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement